Bluebird’s Zynteglo trials set to resume, putting gene therapy back on flight path to FDA filing,

Bluebird Bio’s beta-thalassemia gene therapy Zynteglo has struggled to spread its wings, and a recent clinical pause certainly didn’t help. But with …, Bluebird Bio’s beta-thalassemia gene therapy Zynteglo has struggled to spread its wings, and a recent clinical pause certainly didn’t help. But with …, Read More

Scroll to Top